NO20020151D0 - Veksthormonformuleringer - Google Patents

Veksthormonformuleringer

Info

Publication number
NO20020151D0
NO20020151D0 NO20020151A NO20020151A NO20020151D0 NO 20020151 D0 NO20020151 D0 NO 20020151D0 NO 20020151 A NO20020151 A NO 20020151A NO 20020151 A NO20020151 A NO 20020151A NO 20020151 D0 NO20020151 D0 NO 20020151D0
Authority
NO
Norway
Prior art keywords
hormone formulations
hormone
formulations
Prior art date
Application number
NO20020151A
Other languages
English (en)
Other versions
NO20020151L (no
Inventor
Bernhard Siebold
John Stevens
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020151(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of NO20020151D0 publication Critical patent/NO20020151D0/no
Publication of NO20020151L publication Critical patent/NO20020151L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
NO20020151A 1999-07-12 2002-01-11 Veksthormonformuleringer NO20020151L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (2)

Publication Number Publication Date
NO20020151D0 true NO20020151D0 (no) 2002-01-11
NO20020151L NO20020151L (no) 2002-03-12

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020151A NO20020151L (no) 1999-07-12 2002-01-11 Veksthormonformuleringer

Country Status (25)

Country Link
US (1) US20060029635A1 (no)
EP (1) EP1194170B1 (no)
JP (3) JP2003504346A (no)
KR (1) KR20020031388A (no)
CN (1) CN1360506A (no)
AR (1) AR024728A1 (no)
AT (1) ATE386501T1 (no)
AU (1) AU775107C (no)
BR (1) BR0013162A (no)
CA (1) CA2378949C (no)
CZ (1) CZ200260A3 (no)
DE (1) DE60038118T2 (no)
ES (1) ES2300268T3 (no)
HK (1) HK1046358A1 (no)
HU (1) HUP0202189A3 (no)
IL (2) IL147253A0 (no)
MX (1) MXPA02000404A (no)
NO (1) NO20020151L (no)
NZ (1) NZ516507A (no)
PL (1) PL353238A1 (no)
SI (1) SI1194170T1 (no)
SK (1) SK252002A3 (no)
TR (1) TR200200034T2 (no)
TW (1) TWI247608B (no)
WO (1) WO2001003741A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
AR040526A1 (es) * 2002-07-09 2005-04-13 Grandis Biotech Gmbh Formulaciuones de hgh en alta concentracion que contienen fenol
WO2004082707A2 (en) * 2003-03-18 2004-09-30 Ares Trading Sa Stabilisation of growth hormones in solution
WO2005027960A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
ES2383691T3 (es) * 2003-12-23 2012-06-25 Pharmacia Corporation Formulación líquida estable de hormonas de crecimiento
CA2559918A1 (en) * 2004-04-07 2005-11-10 Tudor Arvinte Liquid growth hormone formulation
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
AU2010321225B2 (en) * 2009-11-17 2015-12-03 Ipsen Pharma S.A.S. Formulation for hGH and rhIGF-1 combination
US20140194356A1 (en) 2011-07-25 2014-07-10 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US20130288968A1 (en) * 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
JP6179690B1 (ja) 2015-12-10 2017-08-16 三菱瓦斯化学株式会社 光硬化性組成物及び光学材料
WO2018142514A1 (ja) * 2017-02-01 2018-08-09 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
WO1992004926A1 (en) * 1990-09-21 1992-04-02 Novo Nordisk A/S Adaptor top
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ATE359824T1 (de) * 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
DK0888127T3 (da) * 1996-02-13 2002-04-08 Searle & Co Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
JP5941496B2 (ja) 2016-06-29
CN1360506A (zh) 2002-07-24
SI1194170T1 (sl) 2008-10-31
MXPA02000404A (es) 2004-05-21
NZ516507A (en) 2004-02-27
NO20020151L (no) 2002-03-12
AU775107B2 (en) 2004-07-15
CA2378949C (en) 2015-03-31
DE60038118T2 (de) 2009-03-05
TR200200034T2 (tr) 2002-05-21
WO2001003741A1 (en) 2001-01-18
SK252002A3 (en) 2002-06-04
WO2001003741B1 (en) 2001-04-19
EP1194170A1 (en) 2002-04-10
HK1046358A1 (zh) 2003-01-10
IL147253A0 (en) 2002-08-14
JP2012051891A (ja) 2012-03-15
HUP0202189A2 (en) 2002-10-28
HUP0202189A3 (en) 2003-07-28
JP2003504346A (ja) 2003-02-04
IL147253A (en) 2007-07-24
KR20020031388A (ko) 2002-05-01
CZ200260A3 (cs) 2002-04-17
BR0013162A (pt) 2002-05-28
CA2378949A1 (en) 2001-01-18
US20060029635A1 (en) 2006-02-09
EP1194170B1 (en) 2008-02-20
AU5997500A (en) 2001-01-30
ES2300268T3 (es) 2008-06-16
TWI247608B (en) 2006-01-21
JP2014208656A (ja) 2014-11-06
AU775107C (en) 2005-02-24
ATE386501T1 (de) 2008-03-15
DE60038118D1 (de) 2008-04-03
AR024728A1 (es) 2002-10-23
PL353238A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
IS6040A (is) Valdekoxib efnablöndur
DK1189853T3 (da) Betonformulering
NO992339L (no) Farmasöytiske formuleringer
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
NO20004240L (no) Formuleringer
IS6120A (is) Lyfjablanda
ATE224703T1 (de) Brauseformulierungen
ATE490327T1 (de) Impfstoffzusammensetzung
EE05421B1 (et) Fulvestrandi formulatsioonid
ATA51899A (de) Handstempel
DK1168916T3 (da) Landbrugskemikalieformuleringer
PT1130966E (pt) Formulacoes antiparasitarias
ATE259590T1 (de) Pour-on formulierungen
EE200200150A (et) Preparaat
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
IS6398A (is) Lyfjablöndur
NO20020151D0 (no) Veksthormonformuleringer
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE60018967D1 (de) Inierzierbare valnemulin formulierung
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
ID27329A (id) Komposisi penghambat
DE50001571D1 (de) Stehhilfe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application